IT-Liver (Inhibiting TGF-β in liver disease) is a Marie Curie Action (People), linked to the Initial Training Network (ITN) program, whose mission is to provide a multidisciplinary and intersectorial Research Training Programme for talented young researchers, so as to prepare them for leading roles in chronic liver disease research and drug discovery in European industry and academia.
One of the most relevant actions is the organization of different scientific events which will provide specific and complementary training in skills, essential for the early-stage researchers to give them a competitive edge. "TGF-β family in fibrosis and cancer" is the final conference of the ITN action and will update the current knowledge about the relevance of the TGF-β pathway in human pathologies, particularly fibrosis and cancer, as well as the most recent advances in the design of therapeutic tools to inhibit it.
Isabel Fabregat on behalf of the IT-LIVER (Marie Curie ITN) European consortium (www.it-liver.eu)
Isabel Fabregat (IDIBELL and University of Barcelona) and Gustavo Egea (University of Barcelona)
Jordi Alcaraz, Elisenda Alsina, Eduard Batlle, Carmelo Bernabeu, Pedro Berraondo, Peter ten Dijke, Steven Dooley, Gustavo Egea, Marta Fierro, Gianluigi Giannelli, Blanca Herrera, Michael Lahn, Stefano Leporatti, Jose Miguel Lopez-Novoa, Wolfgang Mikulits, Maria Molina, Aristidis Moustakas, Miguel Quintanilla, Fernando Rodríguez-Pascual, Aránzazu Sánchez, Joan Seoane, Francesc Viñals.
|Tuesday, 14th June 2016|
|8.45 – 9.00 h||Introduction. IT-LIVER consortium. Isabel Fabregat, IDIBELL and University of Barcelona, Spain.|
Session 1. TGF-beta receptors and signaling
|9.00 – 9.40 h||“Regulation of TGF-beta receptor signaling in cancer”.
Peter ten_Dijke, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
|9.40 – 10.20 h||“TGF-beta signaling in liver physiology and disease”.
Steven Dooley. Faculty of Medicine, Heidelberg University in Mannheim, Germany.
|10.20 – 11.00 h||“NADPH oxidases (NOX) as mediators of the TGF-beta signaling”.
Isabel Fabregat, IDIBELL and University of Barcelona, Spain.
|11.30 – 12.10 h||“Cross-talk between the HGF/MET and TGF-beta signaling pathways in liver cells”.
Aránzazu Sánchez. Complutense University, Madrid, Spain.
|12.10 – 12.50 h||
“Anti-proliferative role of ALK1 receptor in angiogenesis”.
|12.50 – 13.30 h||
“Role of the auxiliary TGF-beta receptor endoglin in pathological angiogenesis and vascular homeostasis” Carmelo Bernabeu. Centro de Investigaciones Biológicas, CIB-CSIC, Madrid, Spain.
Session 2. Role of TGF-beta family in Fibrosis
|15.00 – 15.40 h||
"Role of ALK-1 and endoglin, members of the TGF-beta receptor complex, in kidney fibrosis”. Jose Miguel Lopez-Novoa – Biomedical Research Institute of Salamanca. University of Salamanca, Spain.
|15.40 – 16.20 h||“Smooth muscle cells phenotypic changes and oxidative stress in Marfan syndrome”. Gustavo Egea, University of Barcelona, Spain.|
|16.20 – 17.00 h||"Lysyl oxidases as important factors in vascular fibrosis: a role in aneurysmal disease and myocardial infarction”. Fernando Rodriguez-Pascual. Centro de Biología Molecular Severo Ochoa (CSIC/UAM), Madrid, Spain.|
|17.00 – 17.40 h||"Role of microRNAs in fibrogenesis". Marta Fierro. Centro de Biologia Molecular Severo-Ochoa, (CSIC/UAM), Madrid, Spain.|
|17.40 – 18.20 h||“TGF-beta-Angiotensin cross-talking in lung fibrosis”. Maria Molina. University Hospital of Bellvitge and IDIBELL, Barcelona, Spain.|
Wednesday, 15th June 2016
Session 3. Role of TGF-beta family in Cancer
|9.20 – 9.40 h||Plasticity in tumor cell differentiation. Aristidis Moustakas. Ludwig Institute for Cancer Research and Uppsala University, Sweden.|
|9.40 – 10.20 h||“TGF-beta signaling, metastatic colonization and poor prognosis subtypes in colorectal cancer” Eduard Batlle. Institute for Research in Biomedicine (IRB), Barcelona, Spain.|
|11.30 – 12.10 h||
“The paradoxical role of the TGF-beta coreceptor endoglin in malignant progression". Miguel Quintanilla. Instituto de Investigaciones Biomedicas "Alberto Sols" (CSIC/UAM), Madrid, Spain.
|12.10 – 12.40 h||“Role of BMP9 in liver cancer”. Blanca Herrera. Complutense University, Madrid, Spain.|
|12.40 – 13.10 h||“TGF-beta hyperresponse in tumor associated fibroblasts“. Jordi Alcaraz, University of Barcelona, Spain.|
|13.10 – 13.40 h||“TGF-beta controls IGF1 signalling pathway in ovarian epithelial cancer”. Elisenda Alsina. Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, Barcelona, Spain.|
The TGF-beta pathway as a therapeutic target
Chairs: Michael Lahn, Gianluigi Giannelli
|15.00 – 15.40 h||“Status of TGF-beta inhibitors in clinical investigation“. Michael Lahn. Incyte Europe Sarl. Geneva, Switzerland.|
|15.40 – 16.20 h||“Developing synthetic peptides to block TGF-beta”. Pedro Berraondo. Centro de Investigación Médica Aplicada (CIMA), Pamplona, Spain|
|16.20 – 17.00 h||"Polymeric Nano-carriers as novel tools for TGF-beta inhibitors delivery to HCC Cells". Stefano Leporatti.
CNR NANOTEC - Istituto di Nanotecnologia, Lecce, Italy.
|17.00 – 17.40 h||
“Personalizing therapy in HCC: the case of the TGF-beta pathway”. Gianluigi Giannelli. University of Bari, Italy.
|17.40 – 18.20 h||"Biomarkers of response to anti-TGF-beta agents in cancer". Joan Seoane. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain.|
|18.20 – 18.30 h||Concluding Remarks|
Attendance is free, but registration is required. Coffees will be included. For lunch, attendants will have different possibilities in the School of Medicine, Clinic Hospital and around. Maximum number of attendants is 100.